199 related articles for article (PubMed ID: 25341653)
1. Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.
Massi D; Simi L; Sensi E; Baroni G; Xue G; Scatena C; Caldarella A; Pinzani P; Fontanini G; Carobbio A; Urso C; Mandalà M
Mod Pathol; 2015 Apr; 28(4):487-97. PubMed ID: 25341653
[TBL] [Abstract][Full Text] [Related]
2. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
[TBL] [Abstract][Full Text] [Related]
3. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
4. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
[TBL] [Abstract][Full Text] [Related]
6. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
7. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma.
Barel F; Guibourg B; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Acta Derm Venereol; 2018 Jan; 98(1):44-49. PubMed ID: 28660280
[TBL] [Abstract][Full Text] [Related]
9. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
[TBL] [Abstract][Full Text] [Related]
10. NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma.
Turchini J; Andrici J; Sioson L; Clarkson A; Watson N; Toon CW; Shepherd P; Ng D; Dixon-McIver A; Oei P; Gill AJ
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):475-480. PubMed ID: 26862952
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
12. Cross-reactivity of NRASQ61R antibody in a subset of Spitz nevi with 11p gain: a potential confounding factor in the era of pathway-based diagnostic approach.
Parra O; Lefferts JA; Tafe LJ; Gru AA; Linos K
Hum Pathol; 2021 Jun; 112():35-47. PubMed ID: 33636207
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
[TBL] [Abstract][Full Text] [Related]
14. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
[TBL] [Abstract][Full Text] [Related]
15. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types.
Dias-Santagata D; Su Y; Hoang MP
Am J Clin Pathol; 2016 Jan; 145(1):29-34. PubMed ID: 26712868
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
19. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
20. NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.
Reagh J; Bullock M; Andrici J; Turchini J; Sioson L; Clarkson A; Watson N; Sheen A; Lim G; Delbridge L; Sidhu S; Sywak M; Aniss A; Shepherd P; Ng D; Oei P; Field M; Learoyd D; Robinson BG; Clifton-Bligh RJ; Gill AJ
Am J Surg Pathol; 2017 Jan; 41(1):75-81. PubMed ID: 27635947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]